Sermorelin vs CJC-1295
The GHRH(1-29) fragment once approved to assess and treat GH deficiency. A long-acting GHRH analog engineered to stretch GH pulses. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Sermorelin | CJC-1295 | |
|---|---|---|
| Also known as | — | — |
| Type | Analog | Analog |
| Evidence | Clinical | Limited |
| Family | Growth & repair | Growth & repair |
| Class | GHRH(1-29) analog — the shortest fully active GHRH fragment | GHRH(1-29) analog (with or without a drug-affinity complex) |
| Receptor | GHRH receptor (GHRHR), a class B GPCR | GHRH receptor (GHRHR), a class B GPCR |
| Molecular weight | ≈3,358 Da | ≈3,647 Da |
| Half-life | ~6-8 days (DAC form); ~30 min without DAC | |
| Based on | Growth-hormone-releasing hormone | Growth-hormone-releasing hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Sermorelin and CJC-1295?
- Sermorelin is an engineered analog based on Growth-hormone-releasing hormone; CJC-1295 is an engineered analog based on Growth-hormone-releasing hormone. Sermorelin signals at GHRH receptor (GHRHR), a class B GPCR; CJC-1295 signals at GHRH receptor (GHRHR), a class B GPCR.
- How do the half-lives of Sermorelin and CJC-1295 compare?
- The reported circulating half-life of Sermorelin is ~11-12 min; CJC-1295 is ~6-8 days (DAC form); ~30 min without DAC. These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? CJC-1295 vs Sermorelin. Or open the interactive comparison tool to add more molecules.